Actively Recruiting
Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC)
Led by Murdoch Childrens Research Institute · Updated on 2025-07-18
880
Participants Needed
4
Research Sites
227 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A prospective, open, randomised implementation study in paediatric cancer patients. The study aims to determine whether a personalised approach will result in an overall reduction in clinically relevant adverse drug reactions (ADRs) and to evaluate the economic and quality of life impacts. Participants will be randomised to receive personalised guided prescribing of supportive care therapy (study arm) or standard of care (control arm) for a period of 12 weeks. The follow up period includes prospective patient reporting of symptoms and quality of life through electronically delivered surveys, for a maximum of 12 months.
CONDITIONS
Official Title
Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age less than 18 years
- New cancer diagnosis, or receiving HSCT, or relapsed cancer starting treatment after more than 6 months without treatment
- Starting treatment with a chemotherapeutic agent that is not single agent oral targeted therapy
- Taking a medication with an established CPIC guideline available
- Parent or patient able and willing to give consent and be followed up for at least 12 weeks
- Patient amenable to venepuncture and blood draw or has Whole Genome Sequencing available
- Patient and/or parent able and willing to sign an informed consent form
- Patient and/or parent able to complete Ped-PRO-CTCAE survey in English, Italian, or Chinese
- Study enrolment limit has not been reached
You will not qualify if you...
- Age greater than 18 years
- Life expectancy estimated to be less than three months by treating clinical team
- Planned total treatment length of the drug of inclusion is less than one week
- Patient and/or parent unable or unwilling to consent to or take part in the study
- Patient and/or parent unable to complete Ped-PRO-CTCAE survey in English, Italian, or Chinese
- Patient has existing impaired hepatic or renal function requiring lower dose or alternate drug as part of routine care
- Patient has glomerular filtration rate less than 15 mL/min per 1.73m2
- Patient has advanced liver failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Sydney Children's Hospital
Randwick, New South Wales, Australia, 2031
Actively Recruiting
2
Women's and Children's Hospital
North Adelaide, South Australia, Australia, 5006
Actively Recruiting
3
The Royal Children's Hospital
Parkville, Victoria, Australia, 3052
Actively Recruiting
4
Perth Children's Hospital
Nedlands, Washington, Australia, 6009
Actively Recruiting
Research Team
T
Tayla Stenta
CONTACT
C
Claire Moore
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here